Navigation Links
Sagard Capital Increases Ownership in GP Strategies by 350,000 Shares in a Private Transaction with Bedford Oak Partners, L.P.

ELKRIDGE, Md., Jan. 3, 2012 /PRNewswire/ -- GP Strategies Corporation (NYSE: GPX), a global performance improvement solutions provider of sales and technical training, e-Learning solutions, management consulting and engineering services, today announced that Sagard Capital Partners, L.P. ("Sagard Capital") has agreed to purchase 350,000 shares in a private transaction from Bedford Oak Partners, L.P. The closing of the transaction is subject to customary conditions and is expected to occur within the next week (but in any event prior to January 13th). This purchase increases Sagard Capital's ownership to 3,333,621 shares or 17.8% of GP Strategies' outstanding common stock.  GP Strategies is not a participant in the transaction.

(Logo: )

"We are extremely pleased that an investor like Sagard Capital continues to share our vision on the two-year anniversary of their original private placement.  We view their increased investment as a tangible sign of continued confidence in the direction of GP Strategies," commented Scott N. Greenberg, Chief Executive Officer of GP Strategies.

"We remain enthusiastic about our investment in GP Strategies.  GP Strategies has truly become a leading provider of custom training, consulting and technical services by building a foundation of strong global relationships with their clients," said Dan Friedberg, Managing Partner of Sagard Capital Partners, L.P.  Dan Friedberg is on the Board of Directors and Executive Committee of GP Strategies.

Bedford Oak Partners, L.P., for reasons of its own internal liquidity, decided to sell its shares in GP Strategies before the 2011 calendar year end. Harvey P. Eisen, Chairman of the Board of GP Strategies since April 2005, is also the Chairman and Managing Member of Bedford Oak Advisors, LLC, the investment manager of Bedford Oak Partners, L.P. 

About Sagard Capital Partners, L.P.

Sagard Capital is a long-term impact investor in public and private small and mid-sized companies.  Sagard is an evergreen fund with an indefinite holding period for its investments.  Sagard specializes in flexible transaction structures, making minority investments with equity or debt to best address a company's needs.  Sagard partners with management teams committed to driving long-term shareholder value, through a combination of capital, a global network of relationships, and a team built to deliver value-add support.  Additional information may be found at

About GP Strategies

GP Strategies, a NYSE-listed company (GPX), is a global performance improvement solutions provider of sales and technical training, e-Learning solutions, management consulting and engineering services.  GP Strategies' solutions improve the effectiveness of organizations by delivering innovative and superior training, consulting and business improvement services, customized to meet the specific needs of its clients.  Clients include Fortune 500 companies, manufacturing, process and energy industries, and other commercial and government customers.  Additional information may be found at

Forward Looking Statements

We make statements in this press release that are considered forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934. These statements reflect our current expectations concerning future events and results. We use words such as "expect," "intend," "believe," "may," "should," "could," "anticipates," and similar expressions to identify forward-looking statements, but their absence does not mean a statement is not forward-looking. These statements are not guarantees of our future performance and are subject to risks, uncertainties, and other important factors that could cause our actual performance or achievements to be materially different from those we project. For a full discussion of these risks, uncertainties, and factors, we encourage you to read our documents on file with the Securities and Exchange Commission, including those set forth in our periodic reports under the forward-looking statements and risk factors sections. Except as required by law, we do not intend to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

SOURCE GP Strategies Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Poniard Pharmaceuticals Provides Year-End Clinical Update at 2007 Lazard Capital Markets Healthcare Conference
2. Replidyne to Participate on Anti-infective Panel at RBC Capital Markets Healthcare Conference
3. Paul Capital Healthcare Purchases Additional Royalty Interest in GlaxoSmithKlines Rotarix(R)
4. Aegerion Pharmaceuticals, Inc. adds Peter Garrambone to Board of Directors, Secures Additional Capital for Clinical Trials
5. Foundation Venture Capital Group Invests in UMDNJ Company Working to Improve Leukemia Treatments
6. BioInformatics, LLC New Report - Capitalizing on New Opportunities for Stem Cell Products, Now Available
7. Atlanta-based Med Tech Company CardioMEMS Raises Additional Capital to Advance its CHAMPION Clinical Trial for its Wireless Sensor System for Heart Failure Monitoring
8. Despite Limited Capital Equipment Purchases In 2009, The Global Powered Surgical Instrument Market Held Its Value At $800 Million
9. Baxa Addresses Health-System Capital Shortage With New Programs for IntelliFlowRx(TM) and IntelliFill i.v.(R)
10. New Fall Allergy Capitals(TM) Reveal the Most Challenging Cities for Allergy Sufferers
11. Accumetrics Announces $16.5M in New Capital Financing
Post Your Comments:
(Date:12/1/2015)... 2015   MabVax Therapeutics Holdings, Inc . (OTCQB: ... has filed an Investigational New Drug Application (IND) with ... Company,s lead fully human antibody product HuMab 5B1 as ... to initiate the Phase I clinical trial early in ... The planned Phase I trial will evaluate the ...
(Date:12/1/2015)... FRANCISCO , Dec. 1, 2015  InCarda Therapeutics, ... development and commercialization of therapies for cardiovascular conditions via ... a subsidiary business in Australia . ... trial in Australia in the ... leading investigators and medical centers in Adelaide ...
(Date:12/1/2015)... , Dec. 1, 2015  The migration ... to develop shared care plans that help patients ... care plans will be digitally enabled, incorporate care ... needs and desires. They will also allow all ... patient,s health journey is optimal. That is the ...
Breaking Medicine Technology:
(Date:12/1/2015)... ... December 01, 2015 , ... The Multiple System Atrophy Coalition has announced ... Multiple System Atrophy (MSA) research, timed today to coincide with Giving Tuesday 2015, a ... including their ability to work and be productive, to do simple daily activities like ...
(Date:12/1/2015)... ... December 02, 2015 , ... ClinicoEconomics and Outcomes Research ... of treatment for osteoporosis ”. , As corresponding author Dr Ankita Modi says ... with osteoporosis. Based on a large US managed care database, women aged 55 ...
(Date:12/1/2015)... ... December 01, 2015 , ... According to an ... has filed a discrimination claim against the U.S. Department of Health and Human Services, ... Care Act (ACA) plans are breaking the clause in the law prohibiting the denial ...
(Date:12/1/2015)... ... December 01, 2015 , ... Dr. Paul Vitenas, one of the ... named by MedEsthetics magazine as the Best Single Physician Practice in the nation. Dr. ... elite aesthetic physicians honored by the industry publication. , Dr. Vitenas said he ...
(Date:12/1/2015)... York, NY (PRWEB) , ... December 01, 2015 ... ... epidemic in the 1980s we have seen vast improvements in scientific research and ... made significant strides, providing increased hope and relief to those affected by HIV/AIDS. ...
Breaking Medicine News(10 mins):